Johnson & Johnson (NYSE:JNJ) has entered a clinical supply agreement with GI Innovation to test a bispecific immunotherapy combination in prostate cancer. The collaboration focuses on evaluating J&J’s ...

March 9, 2007 -- A new analysis that compared 3 common treatment options for prostate cancer found a difference between them. Men who were treated with external-beam radiotherapy did not live as long ...

But does it cost too much?

As a result, researchers have explored less invasive options that aim to treat the cancer while preserving quality of life. One such approach is TULSA, which uses real-time MRI guidance to deliver ...

At the recent American Urological Association (AUA) annual meeting, focal therapies for localized prostate cancer took center stage, moving from a niche option to a recognized alternative to surgery ...

SEOUL, South Korea, March 19, 2026 /PRNewswire/ -- GI Innovation announced on 19th that it has entered into a clinical supply agreement with Johnson & Johnson to evaluate a combination therapy in ...

Discover six prostate cancer companies advancing the next generation of therapies for all stages of the disease.

Halda has advanced the next wave of induced proximity drugs into the clinic, expanding the case for bifunctional molecules that act by sticking two proteins together. Whereas the first act for these ...

(UroToday.com) The 2026 European Association of Urology (EAU) annual meeting featured a plenary prostate cancer session and a ...

Explore cancer drug resistance and its significant impact on treatment options and patient outcomes in modern cancer therapy.